Vaccines against components of the renin–angiotensin system

Even though effective drugs for treating hypertension are available, a great percentage of patients have inadequate control of their blood pressure. Unwanted side effects and inappropriate oral drug adherence are important factors that contribute to the global problem of uncontrolled hypertension. Vaccination could provide a revolutionary therapy with long-lasting effects, increasing patient compliance and therefore better control of high blood pressure. Nowadays, current immunization approaches against hypertension target renin, angiotensin I, angiotensin II, and angiotensin II type 1 receptor, key elements of the renin–angiotensin system. This article reviews the different vaccination attempts with proteins and peptides against the different molecules of the renin–angiotensin system in the last two decades, safety issues, and other novel prospects biomarkers in hypertension, and summarizes the potential of this immunomodulatory approach in clinical practice.

• Publication year

  2020

• Venue

  Heart Failure Reviews

• Publication date

  2020-09-29

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/s10741-020-10033-1PMID 32995973PMCID 7524378
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Heat shock protein 60 and cardiovascular diseases: An intricate love‐hate story

  2020cited by this paper
• Loss of balance in normal GPCR-mediated cell trafficking.

  2019cited by this paper
• Counter-regulatory renin–angiotensin system in cardiovascular disease

  2019cited by this paper
• Recent Advances in Therapeutic Vaccines to Treat Hypertension

  2018cited by this paper
• GPCR-specific autoantibody signatures are associated with physiological and pathological immune homeostasis

  2018cited by this paper
• The ATRQβ-001 vaccine improves cardiac function and prevents postinfarction cardiac remodeling in mice

  2018cited by this paper
• Intranasal vaccination against angiotensin II type 1 receptor and pneumococcal surface protein A attenuates hypertension and pneumococcal infection in rodents

  2018cited by this paper
• Antihypertensive drugs

  2017cited by this paper
• AT1 receptor signaling pathways in the cardiovascular system

  2017cited by this paper
• Blood pressure lowering efficacy of renin inhibitors for primary hypertension.

  2017cited by this paper
• Unravelling the Lesser Known Facets of Angiotensin II Type 1 Receptor

  2017cited by this paper
• Immune Response of A Novel ATR-AP205-001 Conjugate Anti-hypertensive Vaccine

  2017cited by this paper
• Circulating blood biomarkers in essential hypertension: a literature review

  2017cited by this paper
• Drug adherence in hypertension

  2017cited by this paper
• Functional autoantibodies targeting G protein-coupled receptors in rheumatic diseases

  2017cited by this paper
• A peptide vaccine targeting angiotensin II attenuates the cardiac dysfunction induced by myocardial infarction

  2017cited by this paper
• Role of the ACE2/Angiotensin 1-7 Axis of the Renin-Angiotensin System in Heart Failure.

  2016cited by this paper
• ATRQ&bgr;-001 vaccine prevents atherosclerosis in apolipoprotein E-null mice

  2016cited by this paper
• Circulating ACE2 activity correlates with cardiovascular disease development

  2016cited by this paper
• Vaccination against type 1 angiotensin receptor prevents streptozotocin-induced diabetic nephropathy

  2015cited by this paper
• New Perspectives in the Renin-Angiotensin-Aldosterone System (RAAS) IV: Circulating ACE2 as a Biomarker of Systolic Dysfunction in Human Hypertension and Heart Failure

  2014cited by this paper
• Hypertension Vaccine may be a boon to millions in developing world

  2014cited by this paper
• The immunological basis of hypertension.

  2014cited by this paper
• Effect of active immunization against angiotensin II type 1 (AT1) receptor on hypertension & arterial remodelling in spontaneously hypertensive rats (SHR)

  2014cited by this paper
• Classical Renin-Angiotensin system in kidney physiology.

  2014cited by this paper
• Decrease in Blood Pressure and Regression of Cardiovascular Complications by Angiotensin II Vaccine in Mice

  2013cited by this paper
• Allergic reactions to vaccines

  2013cited by this paper
• Effects of Textured Insoles on Balance in People with Parkinson’s Disease

  2013cited by this paper
• Therapeutic Vaccines against Human and Rat Renin in Spontaneously Hypertensive Rats

  2013influential reference
• Construction, expression and immunogenicity of a novel anti-hypertension angiotensin II vaccine based on hepatitis A virus-like particle

  2013cited by this paper
• Effectiveness and Safety of a Therapeutic Vaccine Against Angiotensin II Receptor Type 1 in Hypertensive Animals

  2013cited by this paper
• Correction: Ecosystem Carbon and Nitrogen Accumulation after Grazing Exclusion in Semiarid Grassland

  2013cited by this paper
• Renin as a biomarker of cardiovascular disease in clinical practice.

  2012influential reference
• Renin and prorenin as biomarkers in hypertension

  2012cited by this paper
• Renin and prorenin as biomarkers in hypertension

  2012influential reference
• Vaccination against the angiotensin type 1 receptor for the prevention of L-NAME-induced nephropathy

  2012cited by this paper
• A vaccine for hypertension based on peptide AngI-R: a pilot study.

  2011cited by this paper
• Autoantibodies to angiotensin-converting enzyme 2 in patients with connective tissue diseases

  2010cited by this paper
• Immunization against angiotensins for the treatment of hypertension.

  2010cited by this paper
• Local angiotensin II aggravates cardiac remodeling in hypertension.

  2010cited by this paper
• Vaccine hypersensitivity--update and overview.

  2010cited by this paper
• Vaccines in the management of hypertension

  2010cited by this paper
• Morning Surge in Blood Pressure and Cardiovascular Risk: Evidence and Perspectives

  2010cited by this paper
• Success and failure of vaccines against renin–angiotensin system components

  2009cited by this paper
• Vaccine for hypertension: modulating the renin-angiotensin system.

  2009cited by this paper
• Comparison of the immunogenicity and safety of Cervarix™ and Gardasil® human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18–45 years

  2009cited by this paper
• Soluble angiotensin-converting enzyme 2 in human heart failure: relation with myocardial function and clinical outcomes.

  2009influential reference
• Is preeclampsia an autoimmune disease?

  2009cited by this paper
• B-cell tolerance checkpoints in health and autoimmunity.

  2008cited by this paper
• Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study.

  2008cited by this paper
• Pharmacokinetics and pharmacodynamics of aliskiren, an oral direct renin inhibitor.

  2008influential reference
• Antihypertensive Drugs

  2007cited by this paper
• A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity

  2007cited by this paper
• Angiotensin-(1–7) and the renin–angiotensin system

  2007cited by this paper
• Target organ protection from a novel angiotensin II receptor (AT1) vaccine ATR12181 in spontaneously hypertensive rats.

  2006cited by this paper
• Abstract 2753: Observation of Long-Term Efficacy and Safety of an ATR12181 Vaccine Against Hypertension in SHR

  2006cited by this paper
• Immunotherapy: past, present and future

  2003influential reference
• The Gell-Coombs classification of hypersensitivity reactions: a re-interpretation.

  2003cited by this paper
• Evaluation of two carrier protein-angiotensin I conjugate vaccines to assess their future potential to control high blood pressure (hypertension) in man.

  2003cited by this paper
• Interactions between the renin-angiotensin system and dyslipidemia: relevance in the therapy of hypertension and coronary heart disease.

  2003cited by this paper
• Randomized double-blind placebo-controlled study of an angiotensin immunotherapeutic vaccine (PMD3117) in hypertensive subjects.

  2003cited by this paper
• Interactions between the renin-angiotensin system and dyslipidemia: relevance in atherogenesis and therapy of coronary heart disease.

  2001cited by this paper
• Active immunization with angiotensin I peptide analogue vaccines selectively reduces the pressor effects of exogenous angiotensin I in conscious rats

  2000cited by this paper
• Angiotensin II induces LOX-1, the human endothelial receptor for oxidized low-density lipoprotein.

  1999cited by this paper
• Opposing actions of angiotensin-(1-7) and angiotensin II in the brain of transgenic hypertensive rats.

  1995cited by this paper
• Effect of chronic enalapril treatment on enzymes responsible for the catabolism of angiotensin I and formation of angiotensin II.

  1990cited by this paper
• Physiological and immunopathological consequences of active immunization of spontaneously hypertensive and normotensive rats against murine renin.

  1990cited by this paper
• Active immunization against renin in normotensive marmoset.

  1987cited by this paper
• Carrier-induced epitopic suppression, a major issue for future synthetic vaccines.

  1985cited by this paper
• Antirenin in man and animals.

  1951cited by this paper

• Emerging therapeutic frontiers in hypertension management

  2025cites this paper
• Changing the paradigm of long-term blood pressure control: a systematic review of novel therapies

  2025cites this paper
• Salivary microbiome and metabolome profiles associated with dental caries in Tibetan children from high-altitude regions.

  2025cites this paper
• Molecular Challenges and Opportunities in Climate Change-Induced Kidney Diseases

  2024cites this paper
• Targeting aging and age-related diseases with vaccines

  2024influential citation
• Recent Developments in Drug Targets and Combination Therapy for the Clinical Management of Hypertension.

  2023cites this paper
• Development of therapeutic vaccines for the treatment of diseases

  2022cites this paper
• HSP60-Derived Peptide as an LPS/TLR4 Modulator: An in silico Approach

  2022cites this paper
• Clinical Cardiovascular Research Recent trends in “Coronary Artery Disease”

  2022cites this paper
• Immunoneutralization of human angiotensin-(1-12) with a monoclonal antibody IN A HUMANIZED MODEL OF HYPERTENSION.

  2021cites this paper
• From Agonist to Antagonist: Modulation of the Physiological Action of Angiotensins by Protein Conjugation—Hemodynamics and Behavior

  2021cites this paper
• Clinical study on angiotensin II vaccination—the first big step

  2021cites this paper
• Hydroxyapatite Nanoparticles in Drug Delivery: Physicochemistry and Applications

  2021cites this paper
• Peptidic vaccines: The new cure for heart diseases?

  2020cites this paper